4.43

6.75% 0.28

After Hours: 4.44 0.01 +0.23%

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $4.43, with a volume of 6.70M. It is up +6.75% in the last 24 hours and up +26.21% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Previous Close:

$4.15

Open:

$4.15

24h Volume:

6.70M

Relative Volume:

1.63

Market Cap:

$1.35B

Revenue:

$75.13M

Net Income/Loss:

$-146.41M

P/E Ratio:

-9.0334

EPS:

-0.4904

Net Cash Flow:

$-174.43M

1W Performance:

+6.75%

1M Performance:

+26.21%

6M Performance:

-20.18%

1Y Performance:

+77.91%

1-Day Range:

$4.03

$4.47

1-Week Range:

$3.76

$4.47

52-Week Range:

$1.94

$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1113)

Industry

Biotechnology (622)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	4.43	1.27B	75.13M	-146.41M	-174.43M	-0.4904
VRTX Vertex Pharmaceuticals Inc	423.92	108.71B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	74.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.61B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	41.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.81B	5.36B	287.73M	924.18M	2.5229

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

May 01, 2026

AbCellera Biologics Among 3 Promising Penny Stocks - Yahoo Finance

May 01, 2026

Apr 30, 2026

Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Apr 30, 2026

Apr 29, 2026

AbCellera Biologics (NASDAQ:ABCL) Shares Down 7.6%Time to Sell? - MarketBeat

Apr 29, 2026

AbCellera (NASDAQ: ABCL) details 2026 vote on directors, auditor and Say-on-Pay - Stock Titan

Apr 29, 2026

Jones Trading initiates coverage of AbCellera Biologics (ABCL) with buy recommendation - MSN

Apr 29, 2026

Apr 27, 2026

Leerink Partners Downgrades AbCellera Biologics (ABCL) - MSN

Apr 27, 2026

Apr 24, 2026

AbCellera Biologics Pivots to In-House Pipeline, Teases Q3 Phase II Data for ABCL635 Hot Flashes - MarketBeat

Apr 24, 2026

AbCellera Biologics (NASDAQ:ABCL) Stock Price & News - The Motley Fool Canada

Apr 24, 2026

Apr 23, 2026

BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Apr 23, 2026

Apr 22, 2026

JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Apr 22, 2026

AbCellera (ABCL) Positioned Favorably Ahead of Phase 1 Update - GuruFocus

Apr 22, 2026

Apr 21, 2026

ABCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 21, 2026

AbCellera Biologics (ABCL) Is Up 6.8% After Announcing First Human Data Timeline For ABCL635 - simplywall.st

Apr 21, 2026

ABCL: Lead antibody for menopausal hot flashes nears pivotal phase II data, aiming for market differentiation - TradingView

Apr 21, 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - BioSpace

Apr 21, 2026

Apr 20, 2026

AbCellera to share Phase 1 data for menopause drug on May 11 - Investing.com Australia

Apr 20, 2026

JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL) - Insider Monkey

Apr 20, 2026

AbCellera to share Phase 1 data for menopause drug on May 11 By Investing.com - Investing.com South Africa

Apr 20, 2026

Press Release: AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Moomoo

Apr 20, 2026

10 Stocks Under $5 with Huge Upside Potential - Insider Monkey

Apr 20, 2026

Apr 17, 2026